Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  van Herwaarden, Noortje ^a   Den Broeder, Alfons ^a   Jacobs, Wilco ^b   Bijlsma, Johannes W J ^c   Van Vollenhoven, Ronald F ^d   Van den Bemt, Bart J F ^a  

^a SINT MAARTENSKLINIEK   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLINICAL PROTOCOL; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; FOLLOW UP; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

EID: 84908392056     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010455     Document Type: Article

References (35)

1. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology 2005;23(Suppl. 39):S100-S108.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al.2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism 2010;62(9):2569-81.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31(3):315-24.
4. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al.Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007;66(7):921-6.
5. Blumenauer BBTB, Judd M, Wells GA, Burls A, Cranney A, Hochberg MC, et al.Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785].
6. Blumenauer BBTB, Cranney A, Burls A, Coyle D, Hochberg MC, Tugwell P, et al.Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004525].
7. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomised controlled trials. JAMA 2006;295(19):2275-85.
8. Botsios C, Furlan A, Ostuni P, Sfriso P, Todesco S, Punzi L. Effects of low-dose etanercept in maintaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2007; Vol. 66 (Suppl II):54.
9. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al.Effect of discontinuing TNFa antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76(4):350-5.
10. den Broeder AA, Creemers MCW, van Gestel AM, van Riel PLCM. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α. Rheumatology 2002;41(6):638-42.
11. den Broeder AA, van der Maas A, van den Bemt BJF. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology 2010;49(10):1801-3.
12. Doherty M, Dieppe P. The 'placebo' response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage 2009;17(10):1255-62.
13. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, et al.American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials [American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials]. Arthritis and Rheumatism 2011;63(3):573-86.
14. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Clinical Experimental Rheumatology 2005;23(5 Suppl 39):S93-9.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
16. Higgins JPT, Green S (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org..
17. Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise M, Dougados M, Wajdula J. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clinical Experimental Rheumatology 2011;29(2):238-47.
18. Larsen A. A radiological method for grading the severity of rheumatoid arthritis. Scandinavian Journal of Rheumatology 1973;4(4):225-33.
19. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2].
20. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 1995;38(1):44-8.
21. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ESC, et al.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD007649.pub2].
22. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism 1971;14(6):706-20.
23. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopes-Olivo MA, et al.Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2].
24. Singh JA, Noorbaloochi S, Singh. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008341].
25. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al.A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42(2):244-57.
26. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism 2004;50(11):3432-43.
27. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al.Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis:RRR (remission induction by Remicade in RA) study. Annals of the Rheumatic Diseases 2010;69(7):1286-91.
28. van den Bemt BJF, den Broeder AA, Snijders GF, Hekster YA, van Riel PLCM, Benraad B, et al.Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Annals of the Rheumatic Diseases 2008;67(12):1697-1701.
29. van der Bijl AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, ten Wolde S, Han KH, van Krugten MV, et al.Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis and Rheumatism 2007;56(7):2129-34.
30. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al.Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Annals of the Rheumatic Diseases 1990;49(11):916-20.
31. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. Journal of Rheumatology 2000;27(1):261-3.
32. van der Maas A, Kievit W, van den Bemt BJF, van den Hoogen FHJ, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment:an observational cohort study. Annals of the Rheumatic Diseases 2012;71(11):1849-54.
33. van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practise: improvements seen may be explained by a regression-like effect. Annals of the Rheumatic Diseases 2004;63(4):426-30.
34. van Vollenhoven RF. How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Annals of the Rheumatic Diseases 2009;48(11):1237-9.
35. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis and Rheumatism 2006;54(3):711-5.